期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 22, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms22062805
关键词
therapeutic modalities; innovation; diabetes; rheumatoid arthritis; atopic dermatitis; Crohn's Disease; osteoarthritis; migraine; Alzheimer's Disease; Parkinson's Disease
资金
- Eli Lilly and Company
Recent years have seen significant advancements in medicine, with the approval of new drugs and the emergence of novel treatment technologies. Early disease detection, precision intervention, and personalized treatments have revolutionized patient care. This review provides a comprehensive overview of current and emerging therapeutic modalities, focusing on nine diseases in three major therapeutics areas: diabetes, autoimmune disorders, and neurological disorders.
Since 2015, 170 small molecules, 60 antibody-based entities, 12 peptides, and 15 gene- or cell-therapies have been approved by FDA for diverse disease indications. Recent advancement in medicine is facilitated by identification of new targets and mechanisms of actions, advancement in discovery and development platforms, and the emergence of novel technologies. Early disease detection, precision intervention, and personalized treatments have revolutionized patient care in the last decade. In this review, we provide a comprehensive overview of current and emerging therapeutic modalities developed in the recent years. We focus on nine diseases in three major therapeutics areas, diabetes, autoimmune, and neurological disorders. The pathogenesis of each disease at physiological and molecular levels is discussed and recently approved drugs as well as drugs in the clinic are presented.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据